Evidence map›Paper›PMID 36718020›Full record

ArticleThe oncologist2023

Evidence Regarding Pharmacogenetics in Pain Management and Cancer.

D Max Smith, William D Figg

Abstract readComment
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

D Max SmithMedStar Genetic Medicine, MedStar Health, Columbia, MD, USA.ORCID 0000-0003-3667-2936
William D FiggMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5875-2606

Funding

Clinical PharmacogeneticsZIABC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$13.9M
6 · The paper itself

Abstract

Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

Indexed as

Cancer PainNeoplasmsAnalgesics, OpioidCatechol O-MethyltransferaseCytochrome P-450 CYP2D6GenotypeHumansMorphineOxycodonePain ManagementPharmacogeneticsAnalgesics, OpioidCatechol O-MethyltransferaseCytochrome P-450 CYP2D6MorphineOxycodonecancer painopioidspainpharmacogeneticspharmacogenomics

Identifiers

PMID36718020
PMCPMC10020807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.